Print

Lay Description

Objectives

  • Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
  • Secondary: To test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Category

  • Heart, Vascular and Blood
IRB Number
20180178HU
NCT Number
NCT03192215
Open to Enrollment
Yes

Eligibility

Eligible Ages
Over 45 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Exclusion Criteria

Study Design

Arm Groups

Study Contact


Regulatory Point of Contact
Charlotte Rhodes
(210) 450-8454
rhodesc1@uthscsa.edu

Principal Investigator
Reza Behrouz